



**GlaxoSmithKline Pharmaceuticals Ltd.**

GSK House,  
Dr. Annie Besant Road, Worli,  
Mumbai - 400 030  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: [www.gsk-india.com](http://www.gsk-india.com)  
Email: [askus@gsk.com](mailto:askus@gsk.com)

16<sup>th</sup> May 2022

To,

**BSE LIMITED**  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

Dear Sirs,

**Subject: Media release: Q4 & FY21-22**

Please find enclosed a press release issued by the Company in respect of financial results for the quarter and year ended 31<sup>st</sup> March, 2022.

This is for your information and record.

Yours faithfully  
For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President – Administration, Real Estate  
& Company Secretary

CIN: L24239MH1924PLC001151

## GlaxoSmithKline Pharmaceuticals Limited announces results for the full year ended March 31, 2022

**Revenue growth at 12%**  
**Dividend of Rs.90 per equity share**

GlaxoSmithKline Pharmaceuticals Limited today declared its financial results for the year ended March 31, 2022. Revenue for the year from Continuing Operations came in at Rs. 3278 crores recording a growth of 12%. PBT (before exceptional) from Continuing Operations for the year at Rs. 767 crores recorded a growth of 22%. EBITDA margin improved by 3%.

Revenue from Continuing Operations for the quarter ended March 31, 2022 was Rs. 810 crores recording a growth of 9%. PBT (before exceptional) from Continuing Operations for the quarter at Rs. 178 crores recorded a growth of 6%.

Commenting on the results, **Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited**, said, "During the year, our General Medicines portfolio continued to gain market share in their respective categories. Our execution focus on key brands helped us revitalise growth particularly in the anti-infectives, dermatology and pain segments.

While our vaccines business was impacted due to low vaccination rates, many of our key brands gained share in a declining market, fuelled by disciplined execution. We continue to maintain market leadership in the private vaccines market.

During the quarter, we concluded the transfer of *Iodex* and *Ostocalcium* brands to GlaxoSmithKline Asia Private Limited, as part of GSK plc's plans to create two world class companies in pharmaceuticals and consumer healthcare."

The Board recommended a dividend of Rs. 90 per share which includes a special dividend of Rs. 60 per share.

### About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit [www.gsk-india.com](http://www.gsk-india.com)

### Media Contact

Ransom D'Souza  
Communications & Government Affairs  
Email: [ransom.a.dsouza@gsk.com](mailto:ransom.a.dsouza@gsk.com)